Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
News
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa.,…
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa.,…
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
– No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during…
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
– No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during…
Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (NKGen), a clinical-stage…
NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (NKGen), a clinical-stage…
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001
– Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis…
Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001
– Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis…
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…
Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors
ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) — Carina Biotech (Carina), a cell therapy immuno-oncology…
Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors
ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) — Carina Biotech (Carina), a cell therapy immuno-oncology…